Aim: As the impact of angiotensin receptor/neprilysin inhibi-tor (ARNI) on cardiac function in acute myocardial infarc-tion (AMI) patients is unclear in clinical therapy, we conduct-ed this research to investigate the actual effects of improving cardiac function with ARNI in AMI patients. Methods: Publications were checked up to June 2022. Standardised mean differences (SMD) and 95% confidence intervals (CI) were utilised for assessing the size of the effect of continuous variables. To assess the magnitude of the effect of dichotomous variables, a relative risk (RR) with 95% CI was used. Results: ARNI could improve left ventricular ejection frac-tion (SMD = 0.40; 95% CI: 0.23-0.58), while lowering left ventricular end-diastolic volume (SMD = -0.43, 95% CI: -0.78 to -0.08), left ventricular end-systolic volume (SMD = -0.39, 95% CI: -0.66 to -0.11) and left ventricular end-diastolic diameter (SMD = -0.49; 95% CI: -0.65 to -0.33). Besides, it could decrease the rates of major adverse cardiac events (RR = 0.55; 95% CI: 0.43-0.69) and heart failure (RR = 0.42; 95% CI: 0.31-0.58). Conclusion: ARNI could greatly improve cardiac function in AMI patients.